{
  "id": "56c0968def6e394741000026",
  "type": "yesno",
  "question": "Was tamoxifen tested for treatment of glioma patients?",
  "ideal_answer": "Yes, tamoxifen was tested for glioma treatment. However, clinical efficacy of tamoxifen in glioma patients remains unclear and should be tested in further studies.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/9773800",
    "http://www.ncbi.nlm.nih.gov/pubmed/16710748",
    "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
    "http://www.ncbi.nlm.nih.gov/pubmed/9815790",
    "http://www.ncbi.nlm.nih.gov/pubmed/12712458",
    "http://www.ncbi.nlm.nih.gov/pubmed/15022287",
    "http://www.ncbi.nlm.nih.gov/pubmed/12680157",
    "http://www.ncbi.nlm.nih.gov/pubmed/8837815",
    "http://www.ncbi.nlm.nih.gov/pubmed/19810975",
    "http://www.ncbi.nlm.nih.gov/pubmed/20238235",
    "http://www.ncbi.nlm.nih.gov/pubmed/10797257",
    "http://www.ncbi.nlm.nih.gov/pubmed/9266439",
    "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
    "http://www.ncbi.nlm.nih.gov/pubmed/21353747"
  ],
  "snippets": [
    {
      "text": "Tamoxifen might have a role in the initial treatment of high-grade gliomas and should be studied in future Phase II trials building on the newly established platform of concurrent chemoradiotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353747",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20238235",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this study, in which tamoxifen was used in conjunction with radiotherapy, progression free survival was shown to be less good when compared with historical data HR = 3.1 (CI: 1.7-5.7).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20238235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The addition of high-dose tamoxifen, although well tolerated, confers no clinical benefit to patients treated with diffuse intrinsic pontine glioma treated with standard radiotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20238235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Carboplatin and high dose tamoxifen has similar response rates to other regimens for recurrent malignant gliomas and are probably equivalent to those found using tamoxifen as monotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16710748",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Pegylated liposomal doxorubicin administered alone or in combination with tamoxifen is safe and moderately effective in patients with recurrent high-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15022287",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Protein kinase C (PKC) inhibitors such as high-dose tamoxifen and hypericin also have been used in the treatment of malignant gliomas. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712458",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Considering these facts, polyethylene-glycol-liposomal doxorubicin with and without tamoxifen was evaluated within two sequential Phase II trials performed at our institution. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19810975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a parallel phase-II-study investigating post-operative treatment with tamoxifen (TAM), carboplatin and radiation therapy for glioblastomas, 16 of 49 patients (33%) showed multifocal recurrence, which developed after a mean of 46 weeks, raising the question of an association with therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10797257",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: This treatment combination produced no significant change in the overall poor prognosis of these patients. Most tumors responded initially to treatment but recurred as the study progressed. A minority of patients seemed to benefit from the extended use of TX. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tamoxifen, a protein kinase C inhibitor when administered in high dosages, is currently being used as an adjuvant in the treatment of patients with malignant gliomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8837815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present a patient with a recurrent malignant glioma who was continued on high dose tamoxifen despite radiologic documented doubling of the tumor size and who eventually showed a delayed response to this agent nine months after initiation of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9266439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination of oral tamoxifen (120 to 240 mg/m2/day) and subcutaneous interferon-alpha [6 x 10(6) U three times per week] was associated with significant neurotoxicity in this group of recurrent glioma patients, resulting in early study closure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9815790",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21353747",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9266439",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tamoxifen as a potential treatment of glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773800",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We tested the efficacy and toxicity of the combination of high-dose tamoxifen and interferon alpha in adults with recurrent glioma in a phase II trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested the efficacy and toxicity of the combination of high-dose tamoxifen and interferon alpha in adults with recurrent glioma in a phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy of radiation therapy (RT) combined with tamoxifen (TX) was tested in patients diagnosed with diffuse brainstem gliomas in a multicenter trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested the efficacy and toxicity of the combination of high-dose tamoxifen and interferon alpha in adults with recurrent glioma in a phase II trial. Eligible patients had radiographically measurable recurrent gliomas of any grade after initial radiation therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thyroid function was suppressed to reduce IGF-1 levels in glioma patients and high-dose tamoxifen administered.  Propylthiouracil was used to induce chemical hypothyroidism in 22 patients with recurrent glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12680157",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Activity against recurrent gliomas has been reported for both tamoxifen and interferon alpha, agents that have more acceptable toxicity profiles and that can be administered in an outpatient setting. We tested the efficacy and toxicity of the combination of high-dose tamoxifen and interferon alpha in adults with recurrent glioma in a phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thyroid function was suppressed to reduce IGF-1 levels in glioma patients and high-dose tamoxifen administered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12680157",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10715294",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We tested the efficacy and toxicity of the combination of high-dose tamoxifen and interferon alpha in adults with recurrent glioma in a phase II trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The subsequent in vitro testing of the tumor that was removed after the recurrence of tumor (22 months after the initiation of tamoxifen) revealed loss of sensitivity to tamoxifen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8837815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination of oral tamoxifen (120 to 240 mg/m2/day) and subcutaneous interferon-alpha [6 x 10(6) U three times per week] was associated with significant neurotoxicity in this group of recurrent glioma patients, resulting in early study closure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9524096",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013629",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005910",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812"
  ],
  "exact_answer": "Yes"
}